$TTPH Tetraphase Pharmaceuticals to Present at the UBS Global Healthcare Conference
WATERTOWN, Mass., May 09, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (TTPH), a biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant infections, announced today that its corporate presentation will be webcast live at the UBS Global Healthcare Conference on Monday, May 21 at 1:00 p.m. Eastern Time at the Grant Hyatt New York in New York City. Live audio webcasts of the presentation will be available on the company’s website at http://ir.tphase.com/events.cfm. Archived presentations will be available for 30 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multi-drug resistant pathogens highlighted as urgent public health threats by the Centers for Disease Control and Prevention. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which has completed phase 3 clinical trials and is under review for potential approval in complicated intra-abdominal infections by the United States Food and Drug Administration and the European Medicines Agency, and TP-271 and TP-6076, which are in phase 1 clinical trials. Eravacycline is an investigational product only and has not been approved for commercialization. Please visit www.tphase.com for more company information.
Investor & Media Contact:
Tetraphase Pharmaceuticals
Jennifer Viera
617-600-7040
jviera@tphase.com
WATERTOWN, Mass., May 09, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (TTPH), a biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant infections, announced today that its corporate presentation will be webcast live at the UBS Global Healthcare Conference on Monday, May 21 at 1:00 p.m. Eastern Time at the Grant Hyatt New York in New York City. Live audio webcasts of the presentation will be available on the company’s website at http://ir.tphase.com/events.cfm. Archived presentations will be available for 30 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multi-drug resistant pathogens highlighted as urgent public health threats by the Centers for Disease Control and Prevention. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which has completed phase 3 clinical trials and is under review for potential approval in complicated intra-abdominal infections by the United States Food and Drug Administration and the European Medicines Agency, and TP-271 and TP-6076, which are in phase 1 clinical trials. Eravacycline is an investigational product only and has not been approved for commercialization. Please visit www.tphase.com for more company information.
Investor & Media Contact:
Tetraphase Pharmaceuticals
Jennifer Viera
617-600-7040
jviera@tphase.com
Engineer by trade & Swing Trader at Heart!
Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW
CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment
Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW
CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment
